| HOME >> BIOLOGY >> TECHNOLOGY |
development or selling, general and administrative, as appropriate.
CEPHALON, INC. AND SUBSIDIARIES
Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income
(Unaudited)
Three Months Ended
December 31,
2007 2006
GAAP NET INCOME (LOSS) $44,182 $(4,909)
Cost of sales adjustments 26,306 (1) 20,958 (1)
Research and development adjustments 2,000 (2) 35,500 (2) (7)
Selling, general and administrative
adjustments 11,191 (3) - (7)
Acquired in-process research and
development - 5,000 (5)
Debt exchange expense - 48,122 (6)
Income taxes (18,149)(4) (30,831)(4) (7)
21,348 78,749
ADJUSTED NET INCOME $65,530 $73,840
BASIC ADJUSTED INCOME PER COMMON SHARE $0.98 $1.20
DILUTED ADJUSTED INCOME PER COMMON
SHARE $0.83 $1.00
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING 67,187 61,783
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING-ASSUMING DILUTION 78,734 73,633 Notes to Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income
(1) To exclude the on-going amortization of acquired intangible assets.
(2) To exclude charges related to payments for several research and
development collaborations.
(3) To exclude charges related to certain employee
'/>"/>
| SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved |